This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
At the ISPOR Warsaw 2019 regional conference, a panel examined country experiences with managed entry agreements and their impact on improving access to innovative oncology therapies.
This article summarizes the lessons learned from implementing managed entry and multi-year, multi-indication agreements in different regional contexts.
This is the second article in a three-part series examining the commercial dynamics surrounding combination therapy in oncology across the US and Europe. In...
It is difficult to imagine someone who hasn’t called on antibiotics to help them through an infection or protect them during a surgery. Thanks to developments...
